Pharmaceutical - AstraZeneca, Neurological

Filter

Current filters:

AstraZenecaNeurological

Popular Filters

1 to 25 of 26 results

Eli Lilly and AstraZeneca enrol first patient in Phase II/III Alzheimer's therapy trial

Eli Lilly and AstraZeneca enrol first patient in Phase II/III Alzheimer's therapy trial

02-12-2014

US drug major Eli Lilly and AstraZeneca have enrolled the first patient into AMARANTH, a Phase II/III…

AstraZenecaAZD3293Eli LillyNeurologicalPharmaceuticalResearch

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

Neuroscience a key feature of AstraZeneca’s collaboration with University of Cambridge

16-10-2014

Anglo-Swedish drug major AstraZeneca, together with its global biologics R&D arm MedImmune, has entered…

AstraZenecaNeurologicalPharmaceuticalResearchUK

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

24-09-2014

US pharma major Eli Lilly’s recent partnership with Anglo-Swedish peer AstraZeneca to develop oral…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearch

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

AstraZeneca inks neuroscience collaboration with Lieber Institute

AstraZeneca inks neuroscience collaboration with Lieber Institute

04-01-2014

Anglo-Swedish drug major AstraZeneca has entered into a two-year research collaboration with the USA-based…

AstraZenecaNeurologicalPharmaceuticalResearch

AstraZeneca reveals new safety data for naloxegol in OIC

AstraZeneca reveals new safety data for naloxegol in OIC

15-10-2013

AstraZeneca has released results of a Phase III long-term safety and tolerability study of the once-daily…

AstraZenecaGastro-intestinalsnaloxegolNeurologicalPharmaceuticalResearch

Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD

19-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

DC Circuit Court says AstraZeneca not entitled to three-year exclusivity for Seroquel

29-04-2013

In a brief opinion handed down last week by the US Court of Appeals for the District of Columbia Circuit,…

AstraZenecaNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel

Targacept regains rights to Alzheimer's drug candidate from AstraZeneca

06-03-2013

US biopharma drug developer Targacept (Nasdaq: TRGT) and Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AstraZenecaAZD1446LicensingNeurologicalPharmaceuticalResearchTargaceptTC-1734

Encouraging results for AstraZeneca's naloxegol in OIC

26-02-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has announced high-level results from KODIAC-08, an open-label,…

AstraZenecaGastro-intestinalsnaloxegolNeurologicalPharmaceuticalResearch

US Court of Appeals confirms validity of AstraZeneca' Seroquel XR patent

15-02-2013

AstraZeneca announced that, on 14 February 2013, the United States Court of Appeals for the Federal Circuit…

AstraZenecaGenericsLegalNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel XR

Germany invalidates Seroquel patent; Merck drops combo diabetes drug development

14-11-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said last evening that the Federal Patent Court in Germany…

AstraZenecaatorvastatinCardio-vascularDiabetesJanuviaMerck & CoMK-0431ENeurologicalPatentsPharmaceuticalResearchSeroquel XR

Clinical briefs from Novartis, Gilead and AstraZeneca

13-11-2012

Swiss drug major Novartis (NOVN: VX) has released new two-year results from the largest Phase III study…

ACZ885Anti-Arthritics/RheumaticsAnti-viralsAstraZenecaBiotechnologyCerticanGilead SciencesnaloxegolNeurologicalNovartisPharmaceuticalResearchsofosbuvir

Resubmission of aripiprazole NDA accepted; AstraZeneca bond issue

12-09-2012

Danish CNS-focused drugmaker Lundbeck (LUND: DC) and Japanese partner Otsuka Pharmaceutical (TYO: 4668)…

aripiprazole depotAstraZenecaFinancialLundbeckNeurologicalNorth AmericaOtsukaPharmaceuticalRegulation

AstraZeneca buys Link Medicines neuroscience assets; enters Alzheimer's project

12-07-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has acquired a portfolio of neuroscience assets from…

AstraZenecaLink MedicinesMergers & AcquisitionsNeurologicalPharmaceuticalResearch

Slow-down of European bipolar therapy market set for short-term slowdown

04-07-2012

Patent expiry of key blockbuster atypical antipsychotic drugs is likely to cause a decline in growth…

AstraZenecaEuropeGenericsMarkets & MarketingNeurologicalPatentsPharmaceuticalPricingSeroquel

US Court upholds AstraZeneca Seroquel XR patent

30-03-2012

In some good news for the company, Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last night…

Anchen PharmaceuticalsAstraZenecaGenericsMylan LaboratoriesNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel XRTorrent Pharmaceuticals

US court turns down AstraZeneca FDA injunction; Teva debuts generic Seroquel in UK

26-03-2012

In another setback for Anglo-Swedish drug major AstraZeneca in its fight to delay generic competition…

AstraZenecaEuropeGenericsLegalNeurologicalNorth AmericaPatentsPharmaceuticalRegulationSeroquelSeroquel XR

AstraZeneca Seroquel XR patent ruled invalid in UK; eyeing Forest buy?

23-03-2012

In another setback regarding intellectual property on its blockbuster antipsychotic drug, AstraZeneca…

AstraZenecaEuropeForest LaboratoriesLegalNeurologicalPatentsPharmaceuticalSeroquel XR

Astra Zeneca abandons TC-5214 regulatory filing as Ph III fails

20-03-2012

In what is another pipeline disappointment for the company, Anglo-Swedish drug major AstraZeneca (LSE:…

AstraZenecaNeurologicalPharmaceuticalRegulationResearchTargacept

AstraZeneca in deal with Galapagos; view on Seroquel law suit

15-03-2012

BioFocus and Argenta, service companies of Netherlands-based Galapagos (Euronext: GLPG), yesterday announced…

Argenta DiscoveryAstraZenecaBioFocusGalapagosLegalNeurologicalPharmaceuticalResearchRespiratory and PulmonarySeroquelSeroquel XR

AstraZeneca sues US FDA over Seroquel decision

13-03-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced this morning that it has filed a law suit against…

AstraZenecaLegalNeurologicalNorth AmericaPharmaceuticalRegulationSeroquelSeroquel XR

Impax buys US rights to Zomig

01-02-2012

Impax Pharmaceuticals, the branded products business unit of Impax Laboratories (Nasdaq: IPXL) has licensed…

AstraZenecaImpax LaboratoriesLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalZomig

1 to 25 of 26 results

Back to top